Endostar
- Generic Name
- Endostar
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- GVG18ZDN65
- Background
Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Efficacy of Endostar Continuous Infusion Combined with Concurrent Chemoradiotherapy
Endostar continuous infusion combined with concurrent chemoradiotherapy significantly enhances efficacy and safety in treating oesophageal squamous cell carcinoma (OSCC), with higher objective response rates and progression-free survival compared to intravenous drip and standalone chemoradiotherapy.
New Targeted Therapies and Combinations of Treatments in Gynecological Cancer Research
2021 saw significant advances in gynecological cancer research, focusing on cervical, endometrial, and ovarian cancers. Key developments included innovative therapies, improved screening and prevention strategies, and promising results from immunotherapy and antibody-drug conjugates. Despite COVID-19, research remained active, offering hope for future medical practice changes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath